Keyphrases
Survival Analysis
100%
Multiple Myeloma Patients
100%
Newly Diagnosed multiple Myeloma
100%
Transplant Eligibility
100%
Del17p
100%
Overall Survival
50%
Induction Regimen
50%
Bortezomib
50%
Cytogenetic Abnormalities
50%
Maintenance Therapy
50%
5-year Survival
33%
Newly Diagnosed
33%
Progression-free Survival
33%
Latin America (LATAM)
16%
Multivariate Analysis
16%
High Risk
16%
Adult Patients
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Poor Prognosis
16%
Multiple Myeloma
16%
In(III)
16%
Latin American Populations
16%
Positive Impact
16%
Scarce Information
16%
Therapy Groups
16%
Significant Benefit
16%
Median Progression-free Survival
16%
MM Patients
16%
Medicine and Dentistry
Transplantation
100%
Overall Survival
100%
Multiple Myeloma
100%
Survival Analysis
100%
Bortezomib
60%
Progression Free Survival
60%
Maintenance Therapy
60%
Multivariate Analysis
20%
Autologous Stem Cell Transplantation
20%
Group Therapy
20%
Immunology and Microbiology
Transplant Procedure
100%
Overall Survival
100%
Multiple Myeloma
100%
Progression Free Survival
60%
Autologous Stem Cell Transplantation
20%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Multiple Myeloma
100%
Bortezomib
60%
Progression Free Survival
60%
Biochemistry, Genetics and Molecular Biology
Overall Survival
100%
Progression Free Survival
60%
Cytogenetics
60%
Multivariate Analysis
20%
Autologous Stem Cell Transplantation
20%
Agricultural and Biological Sciences
Cytogenetics
100%
Americans
33%
Multivariate Analysis
33%
Autologous Stem Cell Transplantation
33%